Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia

A Phase Ⅰb/Ⅱ, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10380 in Chinese Adults With Schizophrenia.

The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-10380 relative to placebo for the treatment of participants with schizophrenia.

Study Overview

• Status: Not yet recruiting
• Conditions: Schizophrenia
• Intervention / Treatment: Drug: HS-10380; Drug: Placebo

Detailed Description

The trial consists of two parts: dose escalation cohorts and expansion cohorts. The primary aim of the dose escalation cohorts is to evaluate the safety and tolerability of HS-10380 in participants with schizophrenia, and the primary aim of expansion cohorts is to evaluate efficacy of HS-10380 in participants with schizophrenia.

• Study Type: Interventional
• Enrollment (Estimated): 112
• Phase: Phase 2; Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Dose escalation cohorts:

  1. Patients are 18 to 55 years of age, inclusive.
  2. Body mass index (BMI) between 18.5 and 30.0 kg/m2 ,inclusive. Weight ≥ 50 kg for male subjects and ≥ 45 kg for female subjects.
  3. Patient meets DSM-5 criteria for schizophrenia.
  4. Currently not taking antipsychotics. Or on a stable dose of single second-generation antipsychotics (SGA) for at least 2 weeks, limited to either risperidone, olanzapine, quetiapine, aripiprazole, or paliperidone.
  5. PANSS total score ≤ 90. Rating ≤ 4 on hostility and uncooperativeness,
  6. Negative urine pregnancy test (women of childbearing potential only).
  7. Male and female patients must agree to use a highly effective method of birth control during the course of the entire study and for 3 months after the last dose of investigational product.
  8. Written informed consent has been obtained.

Expansion cohorts:

1. Patients are 18 to 65 years of age, inclusive.
2. Patient meets DSM-5 criteria for schizophrenia.
3. No current use of antipsychotics. Or withdrawing from antipsychotics other than clozapine for more than 5 half-lives prior to randomization.
4. PANSS total score ≥70 and ≤120. Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positive symptoms; P1: delusions; P2: conceptual disorganization; P3: hallucinatory behavior; P6: suspiciousness/persecution.
5. Negative urine pregnancy test (women of childbearing potential only).
6. Male and female patients must agree to use a highly effective method of birth control during the course of the entire study and for 3 months after the last dose of investigational product.
7. Written informed consent has been obtained.

Exclusion Criteria:

• Dose escalation cohorts:

  1. Patients meet DSM-5 criteria for a mental illness other than schizophrenia, and might interfere with the conduct of the study as determined by the investigator.
  2. Current risk of self-harm or violence, including: having any suicidal ideation or suicidal behavior within the last 6 months, as assessed using Columbia-Suicidal Severity Rating Scale (C-SSRS).
  3. Patients who have a clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorder, etc. Medical conditions that are minor or well-controlled may be considered acceptable if the condition does not interfere with the conduct of the study.
  4. Patients who received electroconvulsive therapy (ECT) within 3 months prior to screening.
  5. Received a long-acting antipsychotic within 6 months prior to screening or within the duration of 5 half-lives of the drug.
  6. History of seizure disorder (with the exception of febrile seizure).
  7. History of malignant syndrome.
  8. Any condition that would be expected to affect drug absorption, distribution, metabolism and excretion, including gastrointestinal surgery, urinary tract obstruction or difficulty in urination, etc.
  9. History of severe allergies.
  10. Female patients who are pregnant, puerperal or breastfeeding.
  11. History of drug addiction within 1 year prior to screening.
  12. Patients who has a history of alcohol abuse (defined as more than 14 standard units of alcohol consumption per week, 1 standard unit = 360 mL of beer, 45 mL of distilled spirits or 150 mL of wine) within 6 months prior to screening, or are unable to abstain from alcohol use during the study period.
  13. Patients who smoke ≥10 cigarettes per day within 3 months prior to screening, or are unable to quit smoking during the study period.
  14. Abnormal physical examination results that may interfere with the study.
  15. Abnormal vital signs that may interfere with the study, including: resting heart rate <60 or >100 beats per minute, systolic blood pressure <90mmHg or ≥140mmHg, diastolic blood pressure <60mmHg or ≥90mmHg.
  16. Abnormal electrocardiogram (ECG) results may interfere with the study, including: QTcF>450ms for male subjects and >470ms for female subjects based on Fridericia correction.
  17. Abnormal clinical laboratory test results may interfere with the study, including: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) results >1.5 × the upper limit of normal (ULN); serum prolactin levels >5 × ULN or significant clinical symptoms like amenorrhea, gynecomastia, and lactation.
  18. Patients whose results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or syphilis serological reaction (TRUST) is not negative.
  19. Blood donation or blood loss ≥ 200ml within 1 month prior to screening.
  20. Patients requiring concomitant treatment with a moderate or strong cytochrome P450 (CYP) 3A4 inhibitors or CYP3A4 inducers, or a moderate or strong cytochrome CYP2D6 inhibitors or CYP3A4 inducers.
  21. Prior participation in any Interventional clinical trials within 3 months.
  22. Unsuitable for any other reason, as judged by the investigator.

Expansion cohorts:

1. Patients meet DSM-5 criteria for a mental illness other than schizophrenia, and might interfere with the conduct of the study as determined by the investigator.
2. Current risk of self-harm or violence, including: having any suicidal ideation or suicidal behavior within the last 6 months, as assessed using Columbia-Suicidal Severity Rating Scale (C-SSRS).
3. Patients who have a clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorder, etc. Medical conditions that are minor or well-controlled may be considered acceptable if the condition does not interfere with the conduct of the study.
4. Patients who received electroconvulsive therapy (ECT) within 3 months prior to screening.
5. Received a long-acting antipsychotic within 6 months prior to screening or within the duration of 5 half-lives of the drug.
6. History of seizure disorder (with the exception of febrile seizure).
7. History of malignant syndrome.
8. Any condition that would be expected to affect drug absorption, distribution, metabolism and excretion, including gastrointestinal surgery, urinary tract obstruction or difficulty in urination, etc.
9. History of severe allergies.
10. Female patients who are pregnant, puerperal or breastfeeding.
11. History of drug addiction within 1 year prior to screening.
12. Patients who has a history of alcohol abuse (defined as more than 14 standard units of alcohol consumption per week, 1 standard unit = 360 mL of beer, 45 mL of distilled spirits or 150 mL of wine) within 6 months prior to screening, or are unable to abstain from alcohol use during the study period.
13. Abnormal physical examination results that may interfere with the study.
14. Abnormal vital signs that may interfere with the study, including: resting heart rate <60 or >100 beats per minute, systolic blood pressure <90mmHg or ≥140mmHg, diastolic blood pressure <60mmHg or ≥90mmHg.
15. Abnormal electrocardiogram (ECG) results may interfere with the study, including: QTcF>450ms for male subjects and >470ms for female subjects based on Fridericia correction.
16. Abnormal clinical laboratory test results may interfere with the study, including: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) results > 2 × the upper limit of normal (ULN).
17. Patients whose results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or syphilis serological reaction (TRUST) is not negative.
18. Patients requiring concomitant treatment with a moderate or strong cytochrome P450 (CYP) 3A4 inhibitors or CYP3A4 inducers, or a moderate or strong cytochrome CYP2D6 inhibitors or CYP3A4 inducers.
19. Blood donation or blood loss ≥ 200ml within 1 month prior to screening.
20. Prior participation in any Interventional clinical trials within 3 months.
21. Unsuitable for any other reason, as judged by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HS-10380; Participants received HS-10380 tablet orally once daily for 28 days.	Drug: HS-10380; Participants in arm HS-10380 will receiving multiple ascending doses of HS-10380 (1.5 mg initial dose) orally once daily for 28 days
Placebo Comparator: Placebo; Participants received placebo tablet matching HS-10380 1.5mg tablet orally once daily for 28 days.	Drug: Placebo; Participants in arm Placebo will receiving multiple ascending doses of Placebo matching HS-10380 (1.5 mg initial dose) orally once daily for 28 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose escalation cohorts: Incidence and severity of adverse events(AE) ，serious AEs and AE leading to withdrawal from treatment.	An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect.	Baseline to Day 43
Dose escalation cohorts: Changes from baseline in complete blood count (CBC).	Hematology parameters to be reported: white blood cells, red blood cells and platelets.	Baseline to Day 36
Dose escalation cohorts: Changes from baseline in urinalysis.	Parameters to be reported: protein, glucose, ketones, red blood cells, and white blood cells.	Baseline to Day 36
Dose escalation cohorts: Changes from baseline in blood biochemistry test.	Parameters to be reported: glucose, urea, serum creatinine, alanine aminotransferase, aspartate transaminase, albumin, total protein, bilirubin, and blood lipid index.	Baseline to Day 36
Dose escalation cohorts: Changes from baseline in coagulation function test.	prothrombin time, activated partial thromboplastin time and international normalized ratio.	Baseline to Day 36
Dose escalation cohorts: Changes from baseline in thyroid function test.	thyroxine, triiodothyronine, free triiodothyronine, free thyroxin and thyroid stimulating hormone.	Baseline to Day 36
Dose escalation cohorts: Changes from baseline in serum prolactin.	Laboratory test.	Baseline to Day 36
Dose escalation cohorts: Changes from baseline in blood pressure (BP).	Vital sign.	Baseline to Day 36
Dose escalation cohorts: Changes from baseline in pulse rate.	Vital sign.	Baseline to Day 36
Dose escalation cohorts: Changes from baseline in body temperature.	Vital sign.	Baseline to Day 36
Dose escalation cohorts: Change from baseline in body weight	Body weight was measured in kilograms (Kg).	Baseline to Day 29
Dose escalation cohorts: Change from baseline in Electrocardiogram (ECG)	ECG parameters including heart rate, PR interval, RR interval and QTcF, etc.	Baseline to Day 36
Dose escalation cohorts: Change from baseline in Simpson-Angus Scale (SAS)	SAS is a 10-item testing instrument used to evaluate drug-related extrapyramidal syndromes. The following items are included in the SAS: gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella reflex, tremor, and salivation. Total score ranges from 0 to 40 with a higher score indicating increased severity.	Baseline to Day 36
Change from baseline in Abnormal Involuntary Movement Scale (AIMS)	AIMS is a rating scale measuring involuntary movements known as tardive dyskinesia, that sometimes develop as a side effect of long-term treatment with antipsychotic medications. The AIMS score was calculated as the sum of questions 1 through 7 of the AIMS instrument, which includes assessments of involuntary movements in the face, lips, jaw, tongue, upper and lower extremities, and neck/shoulders/hips. Each item is rated on a five-point scale of severity from 0-4 with 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Total scores range from 0 to 28.	Baseline to Day 36
Dose escalation cohorts: Change from baseline in Barnes Akathisia Rating Scale	BARS is a rating scale that is administered by physicians to assess the severity of drug-induced akathisia, which is a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion, as well as by actions such as rocking while standing or sitting, lifting the feet as if marching on the spot, and crossing and uncrossing the legs while sitting. The following subcategories are scored: objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness and are rated on a 4-point scale from 0-3. In addition, the global clinical assessment of akathisia uses a 6-point scale ranging from 0-5. Total score ranges from 0 to 14 with a higher score indicating increased severity.	Baseline to Day 36
Dose escalation cohorts: Change from Baseline in Columbia - Suicide Severity Rating Scale (C-SSRS)	C-SSRS is a scale capturing occurrence, severity, and frequency of suicide-related thoughts and behaviors, and has a binary response (yes/no). Suicidal Ideation: a "yes" answer to any one of 5 suicidal ideation questions: Wish to be Dead, Non-specific Active Suicidal Thoughts, Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act, Active Suicidal Ideation with Some Intent to Act, without Specific Plan, Active Suicidal Ideation with Specific Plan and Intent. Suicidal Behavior: a "yes" answer to any of 5 suicidal behavior questions: Preparatory Acts or Behavior, Aborted Attempt, Interrupted Attempt, Actual Attempt (non-fatal), Completed Suicide.	Baseline to Day 36
Expansion cohorts: Change from Baseline in Positive and Negative Syndrome Scale (PANSS)	PANSS is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210. Higher PANSS total score means more severe outcome.	Baseline to Day 28
Expansion cohorts: Positive and Negative Syndrome Scale (PANSS) Response at Week 4, Defined as a 20% or Greater Improvement from Baseline in PANSS Total Score	PANSS is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210. Higher PANSS total score means more severe outcome.	Baseline to Day 28
Expansion cohorts: Change from Baseline in Clinical Global Impression-Severity (CGI-S)	CGI-S is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The CGI-S a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.	Baseline to Day 28

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose escalation cohorts: Maximum plasma concentration (Cmax) of first HS-10380 administration	Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.	Baseline to Day 36
Dose escalation cohorts: Time of the Maximum Concentration (Tmax) of first HS-10380 administration	Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.	Baseline to Day 36
Dose escalation cohorts: Area under the concentration time curve of intervals (AUC0-τ) of first HS-10380 administration	Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.	Baseline to Day 36
Dose escalation cohorts: Area under the concentration time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC0-t) of first HS-10380 administration	Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.	Baseline to Day 36
Dose escalation cohorts: Maximum concentration at steady state (Css, max) of multiple-dose HS-10380 administration	Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.	Baseline to Day 36
Dose escalation cohorts: Time of the maximum concentration at steady state (Tss, max) of multiple-dose HS-10380 administration	Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.	Baseline to Day 36
Dose escalation cohorts: Minimum concentration at steady state (Css, min) of multiple-dose HS-10380 administration	Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.	Baseline to Day 36
Dose escalation cohorts: Area under the concentration-time curve at steady state (AUCss) of multiple-dose HS-10380 administration	Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.	Baseline to Day 36
Dose escalation cohorts: Apparent clearance at steady state (CLss/F) of multiple-dose HS-10380 administration	Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.	Baseline to Day 36
Dose escalation cohorts: Apparent volume of distribution at steady state (Vss/F) of multiple-dose HS-10380 administration	Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing.	Baseline to Day 36
Dose escalation cohorts: Change from Baseline in Positive and Negative Syndrome Scale (PANSS)	PANSS is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210. Higher PANSS total score means more severe outcome.	Baseline to Day 28
Dose escalation cohort: Positive and Negative Syndrome Scale (PANSS) Response at Week 4, Defined as a 20% or Greater Improvement from Baseline in PANSS Total Score	PANSS is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210. Higher PANSS total score means more severe outcome.	Baseline to Day 28
Dose escalation cohorts: Change from Baseline in Clinical Global Impression-Severity (CGI-S)	CGI-S is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The CGI-S a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.	Baseline to Day 28
Expansion cohorts: Incidence and severity of adverse events(AE) ，serious AEs and AE leading to withdrawal from treatment.	An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect.	Baseline to Day 43
Expansion cohorts: Changes from baseline in complete blood count (CBC).	Hematology parameters to be reported: white blood cells, red blood cells and platelets.	Baseline to Day 36
Expansion cohorts: Changes from baseline in urinalysis.	Parameters to be reported: protein, glucose, ketones, red blood cells, and white blood cells.	Baseline to Day 36
Expansion cohorts: Changes from baseline in blood biochemistry test.	Parameters to be reported: glucose, urea, serum creatinine, alanine aminotransferase, aspartate transaminase, albumin, total protein, bilirubin, and blood lipid index.	Baseline to Day 36
Expansion cohorts: Changes from baseline in coagulation function test	prothrombin time, activated partial thromboplastin time and international normalized ratio.	Baseline to Day 36
Expansion cohorts: Changes from baseline in hyroid function test	thyroxine, triiodothyronine, free triiodothyronine, free thyroxin and thyroid stimulating hormone.	Baseline to Day 36
Expansion cohorts: Changes from baseline in serum prolactin	Laboratory test.	Baseline to Day 36
Expansion cohorts: Changes from baseline in blood pressure (BP)	Vital sign.	Baseline to Day 36
Expansion cohorts: Changes from baseline in pulse rate	Vital sign.	Baseline to Day 36
Expansion cohorts: Changes from baseline in body temperature	Vital sign.	Baseline to Day 36
Expansion cohorts: Change from baseline in body weight	Body weight was measured in kilograms (Kg).	Baseline to Day 29
Expansion cohorts: Change from baseline in Electrocardiogram (ECG)	ECG parameters including heart rate, PR interval, RR interval and QTcF, etc.	Baseline to Day 36
Expansion cohorts: Change from baseline in Simpson-Angus Scale (SAS)	SAS is a 10-item testing instrument used to evaluate drug-related extrapyramidal syndromes. The following items are included in the SAS: gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella reflex, tremor, and salivation. Total score ranges from 0 to 40 with a higher score indicating increased severity.	Baseline to Day 36
Expansion cohorts: Change from baseline in Abnormal Involuntary Movement Scale (AIMS)	AIMS is a rating scale measuring involuntary movements known as tardive dyskinesia, that sometimes develop as a side effect of long-term treatment with antipsychotic medications. The AIMS score was calculated as the sum of questions 1 through 7 of the AIMS instrument, which includes assessments of involuntary movements in the face, lips, jaw, tongue, upper and lower extremities, and neck/shoulders/hips. Each item is rated on a five-point scale of severity from 0-4 with 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Total scores range from 0 to 28.	Baseline to Day 36
Expansion cohorts: Change from baseline in Barnes Akathisia Rating Scale	BARS is a rating scale that is administered by physicians to assess the severity of drug-induced akathisia, which is a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion, as well as by actions such as rocking while standing or sitting, lifting the feet as if marching on the spot, and crossing and uncrossing the legs while sitting. The following subcategories are scored: objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness and are rated on a 4-point scale from 0-3. In addition, the global clinical assessment of akathisia uses a 6-point scale ranging from 0-5. Total score ranges from 0 to 14 with a higher score indicating increased severity.	Baseline to Day 36
Expansion cohorts: Change from Baseline in Columbia - Suicide Severity Rating Scale (C-SSRS)	C-SSRS is a scale capturing occurrence, severity, and frequency of suicide-related thoughts and behaviors, and has a binary response (yes/no). Suicidal Ideation: a "yes" answer to any one of 5 suicidal ideation questions: Wish to be Dead, Non-specific Active Suicidal Thoughts, Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act, Active Suicidal Ideation with Some Intent to Act, without Specific Plan, Active Suicidal Ideation with Specific Plan and Intent. Suicidal Behavior: a "yes" answer to any of 5 suicidal behavior questions: Preparatory Acts or Behavior, Aborted Attempt, Interrupted Attempt, Actual Attempt (non-fatal), Completed Suicide.	Baseline to Day 36

Collaborators and Investigators

• Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): July 30, 2023
• Primary Completion (Estimated): June 30, 2024
• Study Completion (Estimated): December 30, 2024

Study Registration Dates

• First Submitted: July 10, 2023
• First Submitted That Met QC Criteria: July 19, 2023
• First Posted (Actual): July 28, 2023

Study Record Updates

• Last Update Posted (Actual): July 28, 2023
• Last Update Submitted That Met QC Criteria: July 19, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: Schizophrenia; Antipsychotic agents; Psychotropic drug
• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia
• Other Study ID Numbers: HS-10380-201

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No